Indaptus Therapeutics, Inc.

For the period ended Mar 31, 2025. Filed May 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 14, 2025

INDP$2.90-7.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Condensed Consolidated Balance Sheets

	March 31, 2025	December 31, 2024
Assets
Current assets:
Cash and cash equivalents	$3,891,021	$5,786,753
Prepaid expenses and other current assets	1,069,910	831,577
Total current assets	4,960,931	6,618,330
Non-current assets:
Right-of-use asset	58,119	82,175
Other assets - deposits to third parties	392,572	638,251
Total non-current assets	450,691	720,426
Total assets	$5,411,622	$7,338,756
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and other current liabilities	$2,552,379	$3,309,717
Operating lease liability, current portion	59,512	84,164
Total current liabilities	2,611,891	3,393,881
Commitments and contingencies (Note 7)	-	-
Stockholders’ equity:
Common stock: $0.01 par value, 200,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 16,034,444 shares issued and outstanding as of March 31, 2025 and 12,013,901 shares issued and outstanding as of December 31, 2024	160,344	120,139
Preferred stock: $0.01 par value, 5,000,000 shares authorized as of March 31, 2025 and December 31, 2024; no shares issued or outstanding	-	-
Additional paid in capital	67,611,000	64,263,919
Accumulated deficit	(64,971,613)	(60,439,183)
Total stockholders’ equity	2,799,731	3,944,875
Total liabilities and stockholders’ equity	$5,411,622	$7,338,756

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.